This record launch pace supports the narrative of growing clinical adoption and may signal accelerating revenue from Genesis systems and consumables. Monitor the upcoming September 8 symposium for additional center launches or contract announcements, and watch for follow-on orders from Szeged or new European sites.
Price Chart
Executive Summary
Stereotaxis announced that the University of Szeged in Hungary has treated over 70 patients with its Genesis Robotic Magnetic Navigation system within the first month of launch, a record pace of adoption. The press release highlights complex procedures and successful treatment of previously failed ablation cases, signaling growing clinical adoption of Stereotaxis' technology in Europe.
Key Facts
- University of Szeged installed Hungary's first Robotic Magnetic Navigation system in July 2026
- Over 70 patients treated with Genesis system in just over one month, a record pace of use globally
- Patients included paroxysmal and persistent atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular tachycardia
- Robotics enabled successful treatment of patients with multiple previously failed ablation procedures
- University of Szeged to celebrate grand opening of Robotic Cardiology Program at scientific symposium on September 8, 2026
Financial Impact
Record adoption pace could drive incremental Genesis system sales and recurring procedure revenue from consumables, but no deal values or financial figures disclosed
Risk Factors
- No financial figures provided — impact on revenue and earnings is unquantified
- Forward-looking statements about continued adoption carry execution and reimbursement risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3355808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $1.39 $1.18 | ▼ −15.11% | ▼ −13.92% | $0.9900 (−28.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $0.9900 (+28.26%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $0.9900 (+28.26%) |
Aug 11, 2026 10w ago | Press Release | $1.40 $1.30 | ▼ −7.14% | ▼ −5.25% | $0.9900 (−29.29%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▲ +16.36% | ▲ +19.98% | $0.9900 (+40.00%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▼ −16.36% | ▼ −19.98% | $0.9900 (−40.00%) |
Jul 9, 2026 15w ago | 8-K | $1.74 $1.36 | ▼ −21.84% | ▼ −24.08% | $0.9900 (−43.10%) |
May 12, 2026 23w ago | 8-K | $1.85 $1.82 | ▲ +1.62% | ▲ +1.01% | $0.9900 (+46.49%) |
May 12, 2026 23w ago | Press Release | $1.85 $1.82 | ▼ −1.62% | ▼ −1.01% | $0.9900 (−46.49%) |
Apr 21, 2026 26w ago | Press Release | $1.92 $1.78 | ▼ −7.29% | ▼ −12.21% | $0.9900 (−48.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers